1M
CRL icon

13D Management’s Charles River Laboratories CRL Stock Holding History

13D Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.45M Sell
25,800
-2,200
-8% -$408K 6.9% 6
2025
Q4 		$5.59M Hold
28,000
– – 6.65% 6
2025
Q3 		$4.38M Hold
28,000
– – 4.2% 17
2025
Q2 		$4.25M Buy
+28,000
New +$3.73M 3.88% 14

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

13D Management's CRL Position: Q1 2026 in Review

13D Management reduced its Charles River Laboratories (CRL) stake by 7.9% in Q1 2026, selling an estimated $408K and leaving 25,800 shares worth $4.45M. The position accounts for 6.9% of the portfolio, ranked #6.

13D Management first reported a position in CRL in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.59M in Q4 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • 13D Management held 25,800 shares of Charles River Laboratories worth $4.45M as of Q1 2026.
  • 13D Management sold 2,200 Charles River Laboratories shares in Q1 2026, an estimated $408K.
  • Charles River Laboratories made up 6.9% of 13D Management's portfolio in Q1 2026, its #6 holding.
  • 13D Management first reported a position in Charles River Laboratories in Q2 2025 and has held it in 4 quarters since.
  • 13D Management's Charles River Laboratories position peaked at $5.59M in Q4 2025.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on 13D Management's 13F filing for Q1 2026, filed 15 May 2026.